MarketBeat
09 May 2026, 07:12 UTC · 19w ago
Verdict
Headline takes no side. We score VSTM +0.40 across five claims — moderately bullish.
+0.40moderately bullish
More positive than 60% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Verastem advanced its VS-7375 KRAS G12D inhibitor into three registration-directed Phase II trials (TARGET-D 201, 202, 203) across pancreatic, NSCLC, and colorectal cancers following an FDA request for separate protocols.
So whatExpanding a pipeline drug into multiple registration-directed studies significantly broadens the company's total addressable market and future revenue potential.
More positive than 99% of claims this week
Early patients prescribed AVMAPKI FAKZYNJA CO-PACK were further along in their disease journey than expected, leading to earlier-than-anticipated discontinuations.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
First-quarter 2026 net product revenue for AVMAPKI FAKZYNJA CO-PACK came in at $18.7 million, bringing total revenue since the May 2025 launch to nearly $50 million.
More positive than 85% of claims this week
Verastem made targeted changes to its commercial organization and leadership, including appointing a new chief commercial officer, Dan Lyons, following a review of early launch execution challenges.
More negative than 78% of claims this week
A recent physician survey indicated a majority would choose the CO-PACK as their first choice at a patient's next recurrence, and the prescriber base has expanded to more than 400 unique prescribers.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 60% of ticker scores this week
The company reported growth in product revenue and positive physician feedback, though it faced some early commercial execution challenges and patient discontinuations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+63.4%
Price agrees with the score
$7.99 vs $4.89 close before publication (May 8) · not market-adjusted
VSTM chart →